Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

Investors with a lot of money to spend have taken a bearish stance on Boston Scientific (NYSE:BSX). And retail traders should know. We noticed this today when the trades showed up on publicly ...

The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in peripheral interventions. MedSurg segment revenues increased 10.3% to $1.48 billion (10.4% operationally and 7.7 ...

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and ...

Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third quarter powered by the launch of its Farapulse system for atrial ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the ...

Boston Scientific has launched a docuseries campaign to remove the stigma of male incontinence. Across the videos, the campaign tells the stories of how incontinence upended the lives of three men ...

TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $100 from $86 and keeps a Buy rating on the shares. The firm believes they will beat the Street’s 3Q estimates and once ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific reported Q3 revenue of $4.21 billion, beating estimates. EPS reached $0.63, surpassing consensus of $0.59. Cardiovascular sales rose 25%, and MedSurg increased 10.3% ...

Boston Scientific collected a set of FDA green lights for an update to its pulsed field ablation system for atrial fibrillation, allowing it to combine cardiac mapping sensors and therapy delivery ...